The effect of sex/gender on cardiovascular pharmacology

Current Pharmaceutical Design

Volumn 17, Issue 11, 2011, Pages 1095-1107

  Franconi, Flavia ^a   Carru, Ciriaco ^a   Malorni, Walter ^b,c   Vella, Stefano ^b   Mercuro, Giuseppe ^d  

^a UNIVERSITY OF SASSARI   (Italy)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^c UNIVERSITY OF CAGLIARI   (Italy)

^d Istituto San Raffaele   (Italy)

Author keywords

Cardiovascular system; Drug adverse effects; Pharmacodynamics; Pharmacokinetics; Sex gender differences

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ANTILIPEMIC AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CEFRADINE; CYTOCHROME P450; DIGOXIN; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENCAINIDE; ESTRADIOL; FIBRINOGEN RECEPTOR ANTAGONIST; FLECAINIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; MEXILETINE; NIMODIPINE; NISOLDIPINE; PLACEBO; PROPAFENONE; QUINIDINE; SEX HORMONE; UNINDEXED DRUG; WARFARIN;

ACUTE HEART INFARCTION; BIOTRANSFORMATION; BLEEDING; BLOOD FLOW; BODY COMPOSITION; BRAIN ISCHEMIA; CALCIUM CURRENT; CARDIOVASCULAR DISEASE; CLINICAL TRIAL (TOPIC); DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; FEMALE; GENETIC POLYMORPHISM; GLUCURONIDATION; HEART ARRHYTHMIA; HEART OUTPUT; HEART REPOLARIZATION; HUMAN; KIDNEY CLEARANCE; LOW DRUG DOSE; MALE; MENSTRUAL CYCLE; META ANALYSIS (TOPIC); MYALGIA; NONHUMAN; OSTEOPOROSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; QRS COMPLEX; QT PROLONGATION; RESPIRATORY FUNCTION; REVIEW; SEX DIFFERENCE; THROMBOCYTE AGGREGATION INHIBITION; TORSADE DES POINTES; UNSPECIFIED SIDE EFFECT;

EID: 79958206285     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161211795656918     Document Type: Review

References (190)

1. Leinwand LA. Sex is a potent modifier of the cardiovascular system.J Clin Invest 2003; 112: 302-4.
2. Regitz-Zagrosek V. Therapeutic implications of the gender-specificaspects of cardiovascular disease. Nat Rev Drug Discov 2006; 5:425-39.
3. Testimony: National Institutes of Health: Problems in implementingpolicy on women in study populations. Washington, DC: GeneralAccounting Office, July 24, 1990. GAO/T-HRD-90-50.http://archive.gao.gov/d48t13/141859.pdf
4. Wenger NK. Coronary heart disease in women: highlights of thepast 2 years-stepping stones, milestones and obstructing boulders. Nat Clin Pract Cardiovasc Med 2006; 3: 194-202.
5. Rogers W. Evidence-based medicine and women: do the principlesand practice of EBM further women's health? Bioethic 2004; 18:50-71.
6. Pirmohamed M, James S, Meakin S, et al. Adverse drug reactionsac cause of admission to Hospital: prospective analysis of 18820patients. Brit Med J 2004; 329: 15-9.
7. Patel H, Bell D, Molokhia M, et al. Trends in hospital admissionsfor adverse drug reactions in England: analysis of national hospitalepisode statistics 1998-2005. BMC Clin Pharmacol 2007; 7: 9-12.
8. Leach S, Roy S. Adverse drug reactions: an investigation on anacute geriatric ward. Age Ageing 1986; 15: 241-6.
9. Lee PY, Alexander KP, Hammill BG, et al. Representation ofelderly persons and women in published randomized trials of acutecoronary syndromes. J Am Med Ass 2001; 286: 708-13.
10. Gandhi M, Aweeka F, Greenblatt RM, et al. Sex Differences inpharmacokinetics and pharmacodynamics. Annu Rev PharmacolToxicol 2004; 44: 499-523.
11. Rademaker M. Do women have more adverse drug reactions? Am JClin Dermatol 2006; 2: 349-51.
12. Trifiro G, Calogero G, Ippolito FM, et al. Adverse drug events inemergency department population: a prospective Italian study. Pharmacoepidemiol Drug Saf 2005; 14: 333-40.
13. Franconi F, Brunelleschi S, Steardo L, Cuomo V. Gender differencesin drug responses. Pharmacol Res 2007; 55: 81-95.
14. Soldin OP, Mattison DR. Sex differences in pharmacokinetics andpharmacodynamics. Clin Pharmacokinet 2009; 48 143-57.
15. van den Bemt PM, Egberts AC, Lenderink AW, et al. Risk factorsfor the development of adverse drug events in hospitalized patients. Pharm World Sci 2000; 22: 62-6.
16. Key Health Statistics from General Practice 1998-2000 http://www.statistics.gov.uk/statbase/Product.asp?vlnk=4863 Officefor National Statistics, London (last accessed November 23,2006.
17. Heiat A, Gross CP, Krumholz HL, Representation of the elderly,women, and minorities in heart failure clinical trials. Arch InternMed 2002; 162: 1682-8.
18. http://doctor.medscape.com/viewarticle/517016
19. Barsky AJ, Peekna HM, Borus JF. Somatic symptom reporting inwomen and men. J Gen Inter Med 2001; 16: 266-75.
20. Akhter N, Milford-Beland S., Roe MT, et al. Gender differencesamong patients with acute coronary syndromes undergoing percutaneouscoronary intervention in the American College of Cardiology-National Cardiovascular Data Registry (ACC-NCDR). AmHeart J 2009; 157: 141-8.
21. Johnell K, Weitoft GR, Fastbom J. Sex differences in inappropriatedrug use: a register-based study of over 600,000 older people. AnnPharmacother 2009; 43: 1233-9.
22. Anthony M, Berg MJ. Biologic and molecular mechanisms for sexdifferences in pharmacokinetics, pharmacodynamics, and pharmacogenetics.part I. J Womens Health Gend Based Med 2002; 11:601-15.
23. Anthony M, Berg MJ. Biologic and molecular mechanisms for sexdifferences in pharmacokinetics, pharmacodynamics, and pharmacogenetics,part II. J Womens Health Gend Based Med 2002; 11:617-29.
24. Donovan MD. Sex and racial differences in pharmacological response:effect of route of administration and drug delivery systemon pharmacokinetics. J Women Health 2005; 14: 30-7.
25. Kashuba AD, Nafziger AN. Physiological changes during the menstrualcycle and their effects on the pharmacokinetics and pharmacodynamicsof drugs. Clin Pharmacokinet 1998; 34: 203-18.
26. Thurmann PA, Hompesch BC. Influence of gender on the pharmacokineticsand pharmacodynamics of drugs. Int J Clin PharmacolTher 1998; 36: 586-90.
27. Shammas F.V, Dickstein K. Clinical pharmacokinetics in heartfailure. An updated review. Clin Pharmacokinet 1988; 15: 94-113.
28. Catananti C, Liperoti R, Settanni S, et al. Heart failure and adversedrug reactions among hospitalized older adults. Clin PharmacolTher 2009; 86: 307-10.
29. Singh S, Zoble R, Brodsky M, et al. Efficacy and safety of oraldofetilide in converting to and maintaining sinus rhythm in patientswith chronic atrial fibrillation or atrial flutter: the symptomaticatrial fibrillation investigative research on dofetilide [SAFIRE-D]study. Circulation 2000; 102: 2385-90.
30. Hines R.N, Koukouritaki S.B, Poch MT, et al. Regulatory polymorphismsand their contribution to interindividual differences inthe expression of enzymes influencing drug and toxicant disposition. Drug Metab Rev 2008; 40: 263-301.
31. Urquhart BL, Tirona RG, Kim RB. Nuclear receptors and the regulationof drug metabolizing enzymes and drug transporters: implicationsfor interindividual variability in response to drugs. J ClinPharmacol 2007; 47: 566-78.
32. Murray M. Role of signalling systems in the effects of dietaryfactors on the expression of mammalian CYPs. Exp Opin DrugMetab Toxicol 2007; 3: 185-96.
33. Anderson GD Pregnancy-induced changes in pharmacokinetics: amechanistic-based approach. Clin Pharmacokinet 2005; 44: 989-1008.
34. Mann HJ. Drug-associated disease: cytochrome P450 interactions. Crit Care Clin 2006; 22: 329-45.
35. Szyf M. The dynamic epigenome and its implications in toxicology. Toxicol Sci 2007; 100: 7-23.
36. Cotreau MM, von Moltke LL, Greenblatt DJ. The influence of ageand sex on the clearance of cytochrome P450 3A substrates. ClinPharmacokinet 2005; 44: 33-60.
37. Schwartz JB. The current state of knowledge on age, sex, and theirinteractions on clinical pharmacology. Clin Pharmacol Ther 2007;82: 87-92.
38. Doki K, Homma M, Kuga K, et al. Gender-associated differencesin pharmacokinetics and anti-arrhythmic effects of flecainide inJapanese patients with supraventricular tachyarrhythmia. Eur J ClinPharmacol 2007; 63: 951-7.
39. Flockhart DA. Drug Interactions: Cytochrome P450 drug interactiontable. Indiana University School of Medicine [2007]
40. Thurmann PA, Haack S, Werner U, et al. Tolerability of β-blockersmetabolized via cytochrome P450 2D6 is sex-dependent. ClinPharmacol Ther 2006; 80: 551-3.
41. Hagg S, Spigset O, Dahlqvist R. Influence of gender and oral contraceptiveson CYP2D6 and CYP2C19 activity in healthy volunteers. Brit J Clin Pharmacol 2001; 51: 169-73.
42. Hunt CM, Westerkam WR, Stave GM. Effect of age and gender onthe activity of human hepatic CYP3A. Biochem Pharmacol 1992;44: 275-83.
43. Zhu B, Liu ZQ, Chen GL, et al. The distribution and gender differenceof CYP3A activity in Chinese subjects. Brit J Clin Pharmacol 2003; 55: 264-9.
44. Flockhart DA, Rae JM. Cytochrome P450 3A pharmacogenetics:the road that needs traveled. Pharmacogenomics J 2003; 3: 3-5.
45. Holazo AA, Winkler MB, Patel IH. Effects of age, gender and oralcontraceptives on intramuscular midazolam pharmacokinetics. JClin Pharmacol 1988; 28: 1040-5.
46. Kashuba AD, Bertino JS, Rocci, ML, et al. Quantification of 3-month intraindividual variability and the influence of sex and menstrualcycle phase on CYP3A activity as measured by phenotypingwith intravenous midazol. Am Clin Pharmacol Ther 1998; 64: 269-77.
47. Kawai M, Bandiera SM, Chang TK, et al. Growth hormone regulationand developmental expression of rat hepatic CYP3A18,CYP3A9, and CYP3A2. Biochem Pharmacol 2000; 59: 1277-87.
48. Anakk S, Ku CY, Vore M, Insights into Gender Bias: Rat CytochromeP450 3A9. J Pharmacol Exp Ther 2003; 305: 703-9.
49. Thummel KE. Wilkinson GR. In vitro and in vivo drug interactionsinvolving human CYP3A. Annu Rev Pharmacol Toxicol 1998; 38:389-30.
50. Waxman DJ, Holloway MG. Sex differences in the expression ofhepatic drug metabolizing enzymes. Mol Pharmacol 2009; 76: 215-28.
51. Ostadal B, Netuka I, Maly J, et al. Gender differences in cardiacischemic injury and protection-experimental aspects. Exp Biol Med 2009; 234 1011-9.
52. Malorni W, Campesi I, Straface E, et al. Redox features of the cell:a gender perspective. Antioxid Redox Signal 2007; 9: 1779-801.
53. Kneale BJ, Chowienczyk PJ, Brett SE, et al, Gender differences insensitivity to adrenergic agonists of forearm resistance vasculature. J Am Coll Cardiol 2000; 36: 1233-8.
54. Pretorius M, Luther JM, Murphey LJ, et al. Angiotensin-convertingenzyme inhibition increases basal vascular tissue plasminogen activatorrelease in women but not in men. Arterioscler Thromb VascBiol 2005; 25: 2435-40.
55. De Silva TM, Broughton BR, Drummond GR. Gender influencescerebral vascular responses to angiotensin II through Nox2-derivedreactive oxygen species. Stroke 2009; 40: 1091-1097.
56. Arias-Loza PA, Jazbutyte V, Pelzer T. Genetic and pharmacologicstrategies to determine the function of estrogen receptor a and estrogenreceptor b in the cardiovascular system. Gend Med 2007; 5:S34-45.
57. Malorni W, Straface E, Matarrese P, et al. Redox state and genderdifferences in vascular smooth muscle cells. FEBS Lett 2008; 582:635-42.
58. Zhu Y, Bian Z, Lu P, et al. Abnormal vascular function and hypertensionin mice deficient in estrogen receptor beta. Science 2002;295: 505-8.
59. Kleinert H, Wallerath T, Euchenhofer C, et al. Estrogens increasetranscription of the human endothelial NO synthase gene: analysisof the transcription factors. Hypertension 1998; 31: 582-8.
60. Bae S, Zhang L. Gender differences in cardioprotection againstischemia/reperfusion injury in adult rat hearts: focus on akt andprotein kinase C signaling. J Pharmacol Exp Ther 2005; 315: 1125-35.
61. Camper-Kirby D, Welch S, Walker A, et al. Myocardial akt activationand gender: increased nuclear activity in females versus males. Circ Res 2001; 88: 1020-7.
62. Tostes RC, Fortes ZB, Callera GE, et al. Endothelin, sex and hypertension. Clin Sci 2008; 114: 85-97.
63. Tsang S, Wu S, Liu J, et al Testosterone protects rat hearts againstischaemic insults by enhancing the effects of alpha[1]-adrenoceptorstimulation. Brit J Pharmacol 2008; 153: 693-709.
64. English KM, Mandour O, Steeds RP, et al. Men with coronaryartery disease have lower levels of androgens than men with normalcoronary angiograms. Eur Heart J 2000; 21: 890-4.
65. English KM, Steeds RP, Jones TH, et al. Low-dose transdermaltestosterone therapy improves angina threshold in men with chronicstable angina: a randomized, double-blind, placebo-controlledstudy. Circulation 2000; 102: 1906-11.
66. Malkin CJ, Pugh PJ, Morris PD, et al. Testosterone replacement inhypogonadal men with angina improves ischaemic threshold andquality of life. Heart 2004; 90: 871-4.
67. Pilote L, Dasgupta K, Guru V, et al. A comprehensive view of sexspecificissues related tocardiovascular disease. CMAJ 2007; 176:S1-44.
68. Jochmann N, Stangl K, Garbe E, et al. Females pecific aspects inthe pharmacotherapy of chronic cardiovascular diseases. Eur HeartJ 2005; 26: 1585-95.
69. Hsich EM, Pina IL. Heart failure in women: a need for prospectivedata. J Am Coll Cardiol 2009; 54: 491-8.
70. Stramba-Badiale M, Priori SG. Gender-specific prescription forcardiovascular diseases? Eur Heart J 2005; 26: 1571-2.
71. Sica DA, Wood M, Hess M. Gender and its effect in cardiovascularpharmacotherapeutics: recent considerations. Congest. Heart Fail 2005; 11: 163-6.
72. Berger JS, Bhatt DL, Cannon CP. et al. The relative efficacy andsafety of clopidogrel in women and men a sex-specific collaborativemeta-analysis. J Am Coll Cardiol 2009; 54: 1935-45.
73. Bazett HC. An analysis of the time-relations of electrocardiograms. Heart 1920; 7: 353-70.
74. Rautaharju PM, Zhou SH, Wong S, et al. Sex differences in theevolution of the electrocardiographic QT interval with age. Can JCardiol 1992; 8: 690-5.
75. James AF, Choisy SC, Hancox JC. Recent advances in understandingsex differences in cardiac repolarization. Prog Prog BiophysMol Biol 2007; 94: 265-319.
76. Yarnoz MJ, Curtis AB. More reasons why men and women are notthe same (gender differences in electrophysiology and arrhythmias). Am J Cardiol 2008; 101: 1291-6.
77. Stramba-Badiale M, Locati EH, Martinelli A, et al. Gender and therelationship between ventricular repolarization and cardiac cyclelength during 24-h Holter recordings. Eur Heart J 1997; 18: 1000-6.
78. Kurokawa J, Suzuki T, Furukawa T, et al. New aspects for thetreatment of cardiac diseases based on the diversity of functionalcontrols on cardiac muscles: acute effects of female hormones oncardiac ion channels and cardiac repolarization. J Pharmacol Sci 2009; 109: 334-40.
79. Anthony MJ. Male/female differences in pharmacology: safetyissues with QT-prolonging drugs. Women's Health (Larchmt) 2005; 14: 47-52.
80. Okin PM, Roman MJ, Devereux RB, Kligfield P. Gender differencesand the electrocardiogram in left ventricular hypertrophy. Hypertension 1995; 25: 242-9.
81. Rautaharju P, Kooperberg C, Larson J, Lacroix A. Electrocardiographicabnormalities that predict coronary heart disease events andmortality in postmenopausal women. Circulation 2006; 113: 473-80
82. Lawrence CL, Pollard CE, Hammond TG, et al. Nonclinical proarrhythmiamodels: predicting Torsades de Pointes. J PharmacolToxicol Methods 2005; 52: 46-59.
83. Essebag V, Reynolds MR, Hadjis T, et al. Sex differences in therelationship between amiodarone use and the need for permanentpacing in patients with atrial fibrillation. Arch Intern Med 2007;167: 1648-53.
84. Martino E, Bartalena L, Bogazzi F, et al. Effects of amiodarone onthe thyroid. Endocr Rev 2001; 22: 240-54.
85. Dusman RE. Clinical features of amiodarone-induced pulmonarytoxicity. Circulation 1990; 82: 51-9.
86. Wyse DG, Hallstrom A, McBride R, et al. Events in the CardiacArrhythmia Suppression Trial [CAST]: mortality in patients survivingopen label titration but not randomized to double-blind therapy. J Am Coll Cardiol 1991; 18: 20-8.
87. Borchers AT, Keen CL, Gershwin ME, et al. Drug-induced lupus. Ann NY Acad Sci 2007; 1108: 166-82.
88. The effect of digoxin on mortality and morbidity in patients withheart failure. The Digitalis Investigation Group. N Engl J Med 1997; 336: 525-33.
89. Rathore SS, Wang Y, Krumholz HM. Sex-based differences in theeffect of digoxin for the treatment of heart failure. N Engl J Med 2002; 347: 1403-11.
90. Aarnoudse AL, Dieleman JP, Stricker BH, et al. Age- and genderspecificincidence of hospitalisation for digoxin. Drug Saf intoxication 2007; 30: 431-6.
91. Pedone C, Corsonello A, Carosella L, et al. Comparison of digitalis-related adverse events in hospitalized men and women in Italy:an observational study. Clin Ther 2005; 27: 1922-9.
92. Green HJ, Duscha BD, Sullivan MJ, et al. Normal skeletal muscleNa[+]-K[+] pump concentration in patients with chronic heart failure. Muscle Nerve 2001; 24: 69-76.
93. Rahman AR, McDevitt DG, Struthers AD, et al. Sex differences inhypokalemic and electrocardiographic effects of inhaled terbutaline. Thorax 1992; 47: 1056-60.
94. Freedman RR, Sabharwal SC, Desai N. Sex differences in peripheralvascular adrenergic receptors. Circ Res 1987; 61: 581-4.
95. Cohen RA, Coffman JD. b-adrenergic vasodilator mechanism inthe finger. Circ Res 1981; 49: 1196-201.
96. Wheeldon MM, Newnham DM, Coutie WJ, et al. Influence of sexsteroidhormones on the regulation of lymphocyte b2-adrenoceptors during the menstrual cycle. Brit J Clin Pharmacol 1994; 37: 583-8.
97. Mills PJ, Ziegler MG, Nelesen RA, et al. The effects of menstrualcycle, race and gender on adrenergic receptors and agonists. ClinPharmacol Ther 1996; 60: 99-104.
98. Freemantle N, Cleland J, Young P, et al. beta Blockade after myocardialinfarction: systematic review and meta regression analysis. BMJ 1999; 318: 1730-7.
99. Silvet H, Spencer F, Yarzebski J, et al. Community wide trends inthe use and outcomes associated with beta-blockers in patients withacute myocardial infarction: the Worcester Heart Attack Study. Arch Intern Med 2003; 163: 2175-83.
100. Krumholz HM, Radford MJ, Wang Y, et al. National use and effectivenessof {beta}-blockers for the treatment of elderly patients afteracute myocardial infarction: National Cooperative CardiovascularProject. JAMA 1998; 280: 623-9.
101. Turnbull F, Woodward M, Neal B, et al. Do men and women responddifferently to blood pressure-lowering treatment? Results ofprospectively designed overviews of randomized trials. Eur Heart J 2008; 29: 2669-80.
102. Gueyffier F, Boutitie F, Boissel JP, et al. Effect of antihypertensivedrug treatment on cardiovascular outcomes in women and men. Ameta-analysis of individual patient data from randomized, controlledtrials. The INDANA Investigators. Ann Intern Med 1997;126: 761-9.
103. Lim LS, Fink HA, Blackwell T. et al. Loop diuretic use and ratesof hip bone loss and risk of falls and fractures in older women. JAm Geriatr Soc 2009; 57: 855-60.
104. Widmer P, Maibach R, Künzi UP, Capaul R, Mueller U, Galeazzi R, et al. Diuretic-related hypokalaemia: the role of diuretics, potassiumsupplements, glucocorticoids and beta 2-adrenoceptor agonists.Results from the comprehensive hospital drug monitoringprogramme, berne (CHDM). Eur J Clin Pharmacol 1995; 49: 31-6.
105. Cohen N, Ilgiyaev E, Almoznino-Sarafian D, et al. Sex-relatedbedside clinical variables associated with survival of older inpatientswith heart failure. Eur J Heart Fail 2004; 6: 781-9.
106. Franson KL, Kuk JM, Lam NP, et al. Gender effect on diureticresponse to hydrochlorothiazide and furosemide. Int J Clin PharmacoTher 1996; 34: 101-5.
107. Knowles SR, Wong GA, Rahim SA, et al. Hydrochlorothiazideinducednoncardiogenic pulmonary edema: an underrecognized yetserious adverse drug reaction. J Invasive Cardiol 2005; 25: 1258-65.
108. Brown N, Vaughan D. Angiotensin converting enzyme inhibitors. Circulation 1998; 97: 1411-20.
109. Heart Outcomes Prevention Evaluation Study Investigators. Effectsof an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascularevents in high-risk patients. N Engl J Med 2000; 342: 45-153.
110. Strippoli GF, Craig M, Deeks JJ, Schena FP, Craig JC. Effects ofangiotensin converting enzyme inhibitors and angiotensin II receptorantagonists on mortality and renal outcomes in diabetic nephropathy:systematic review. BMJ 2004; 329: 828.
111. Kjeldsen SE, Julius S. Hypertension mega-trials with cardiovascularend points: effect of angiotensin-converting enzyme inhibitorsand angiotensina receptor blockers. Am Heart J 2004; 148: 747-54.
112. Walsh JME, Pignone M. Drug treatment of hyperlipidemia inwomen. J Am Med Ass 2004; 291: 2243-52.
113. Hunt SA. American College of Cardiology; American Heart AssociationTask Force on Practice Guidelines ACC/AHA 2005 guidelineupdate for the diagnosis and management of chronic heart failurein the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines(Writing Committee to Update the 2001 Guidelines for theEvaluation and Management of Heart Failure). J Am Coll Cardiol 2005; 46: e1-e82.
114. Garg R, Yusuf S. Overview of randomized trials of angiotensinconvertingenzyme inhibitors on mortality and morbidity in patientswith heart failure. Collaborative Group on ACE Inhibitor Trials. JAm Med Ass 1995; 273: 1450-6.
115. Shekelle PG, Rich MW, Morton SC, et al. Efficacy of angiotensinaconverting enzyme inhibitors and beta-blockers in the managementof left ventricular systolic dysfunction according to race, gender,and diabetic status: a meta-analysis of major clinical trials. J AmColl Cardiol 2003; 41: 1529-38.
116. Lonn E, Roccaforte R, Yi Q, Dagenais G, et al. Effect of long-termtherapy with ramipril in high-risk women. J Am Coll Cardiol 2002;40: 693-702.
117. Keyhan G, Chen SF, Pilote L. Angiotensin-converting enzymeinhibitors and survival in women and men with heart failure. Eur JHeart Failure 2007; 9: 594-601.
118. Kostis JB, Shelton B, Gosselin G, et al. Adverse effects of enalaprilin the Studies of Left Ventricular Dysfunction (SOLVD). Am HeartJ 1996; 131: 350-5.
119. Bangdiwala SI, Weiner DH, Bourassa MG, et al. Studies of LeftVentricular Dysfunction (SOLVD) Registry: rationale, design,methods and description of baseline characteristics. Am J Cardiol 1992; 70: 347-53.
120. Os I, Bratland B, Dahlöf B, et al. Female preponderance for coughin hypertension. Am J Hypertens 1994; 7: 1012-15.
121. Shah MR, Granger CB, Bart BA, et al. Sex-related differences inthe use and adverse effects of angiotensin-converting enzyme inhibitorsin heart failure: the study of patients intolerant of convertingenzyme inhibitors registry. Am J Med 2000; 109: 489-92.
122. Vleeming W, van Amsterdam JG, Stricker BH, et al. ACE inhibitor-induced angioedema. Incidence, prevention and management. Drug Safety 1998; 18: 171-88.
123. Miller DR., Oliveria SA, Berlowitz DR, et al. Angioedema incidencein US veterans initiating angiotensin-converting enzyme inhibitors.Hypertension 2008; 51: 1624-30.
124. Gerdts E, Okin P.M, de Simone G, et al. Gender differences in leftventricular structure and function during antihypertensive treatment:the Losartan Intervention for Endpoint Reduction in HypertensionStudy. Hypertension 2008; 51: 1109-1114.
125. Os I, Franco V, Kjeldsen S.E. et al. Effects of losartan in womenwith hypertension and left ventricular hypertrophy: results from theLosartan Intervention for Endpoint Reduction in Hypertension Study. Hypertension 2008; 51: 1103-8.
126. Zanchetti A, Julius S, Kjeldsen S, et al. Outcomes in subgroups ofhypertensive patients treated with regimens based on valsartan andamlodipine: an analysis of findings from the VALUE trial. J Hypertens 2006; 24: 2163-8.
127. Mann J, Julius S. The Valsartan Antihypertensive Long-Term UseEvaluation [VALUE] trial of cardiovascular events in hypertension.Rationale and design. Blood Press 1998; 7: 176-83.
128. Hudson M, Rahme E, Behlouli H. Sex differences in the effectivenessof angiotensin receptor blockers and angiotensin convertingenzyme inhibitors in patients with congestive heart failure-a populationstudy. Eur J Heart Failure 2007; 9: 602-9.
129. Daniel KR, Wells G, Stewart K, Moore B, Kitzman DW. Effect ofaldosterone antagonism on exercise tolerance, Doppler diastolicfunction, and quality of life in older women with diastolic heartfailure. Congest Heart Fail 2009; 15: 68-74.
130. Galvao M, Kalman J, DeMarco T, et al. Gender differences in inhospitalmanagement and outcomes in patients with decompensatedheart failure: analysis from the Acute Decompensated Heart FailureNational Registry (ADHERE). J Card Fail 2006; 12: 100-107.
131. Nieminen MS, Harjola VP, Hochadel M, et al. Gender relateddifferences in patients presenting with acute heart failure. Resultsfrom EuroHeart Failure Survey II. Eur J Heart Fail 2008; 10: 140-8.
132. Mak GJ, Ledwidge MT, Watson CJ, et al. Natural history of markersof collagen turnover in patients with early diastolic dysfunctionand impact of eplerenone. J Am Coll Cardiol 2009; 54: 1674-82.
133. ALLHAT Officers and Coordinators for the ALLHAT CollaborativeResearch Group. The Antihypertensive and Lipid-LoweringTreatment to Prevent Heart Attack Trial. Major outcomes in highriskhypertensive patients randomized to angiotensin-convertingenzyme inhibitor or calcium channel blocker vs diuretic: J Am MedAss 2002; 288: 2981-97.
134. Brown MJ, Palmer CR, Castaigne A, et al. Morbidity and mortalityin patients randomised to double blind treatment with a long-actingcalcium-channel blocker or diuretic in the International NifedipineGITS study: Intervention as a Goal in Hypertension Treatment[INSIGHT]. Lancet 2000; 356: 366-70.
135. Fagard RH, Staessen JA, Thijs L, et al. Response to antihypertensivetherapy in older patients with sustained and nonsustained systolichypertension. Circulation 2000; 102: 1139-42.
136. Hansson L, Lindholm LH, Ekborn T, et al. Randomised trial of oldand new antihypertensive drugs in elderly patients: cardiovascularmortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999; 354: 1751-6.
137. Kjeldsen S.E, Hedner T, Syvertsen J.O, et al. Influence of age, sexand blood pressure on the principal endpoints of the Nordic Diltiazem[NORDIL] Study. J Hypertens 2002; 20: 1231-1237.
138. Kloner R.A, Sowers J.R, DiBona G.F, et al. for the AmlodipineCardiovascular Community Trial Study Group. Sex- and agerelatedantihypertensive effects of amlodipine. Am J Cardiol 1996;77: 713-722.
139. Kjeldsen SE, Kolloch RE, Leonetti G, et al. Influence of genderand age on the preventing cardiovascular disease by antihypertensivetreatment and acetysalicyl acid. The HOT Study. J Hypertens 2000; 18: 629-642.
140. Bass KM, Newschaffer CJ, Klag MJ, Bush TL. Plasma lipoproteinlevels as predictors of cardiovascular death in women. Arch InternMed 1993; 153: 2209-16.
141. Sharrett AR, Ballantyne CM, Coady SA, et al. Coronary heartdisease prediction from lipoprotein cholesterol levels, triglycerides,lipoprotein(a;, apolipoproteins A-1 and B, and HDL density subfractions:the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 2001; 104: 1108-13.
142. Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoproteincholesterol and cardiovascular disease: four prospectiveAmerican studies. Circulation 1989; 79: 8-15.
143. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factorfor cardiovascular disease independent of high-density lipoproteincholesterol level: a meta-analysis of population-based prospectivestudies. J Cardiovasc Risk 1996; 3: 213-9.
144. Johnson CL, Rifkind BM, Sempos CT, et al. Declining serum totalcholesterol levels among US adults: the National Health and NutritionExamination Surveys. J Am Med Assoc 1993; 269: 3002-8.
145. Rosenberg H, Allard D. Women and statin use: a women's healthadvocacy perspective. Scand Cardiovasc J 2008; 42: 268-74.
146. Expert Panel on Detection, Evaluation, and Treatment of HighBlood Cholesterol in Adults. Third report of the National CholesterolEducation Program [NCEP] Expert Panel on Detection,Evaluation, and Treatment of High Blood Cholesterol in Adults[Adult Treatment Panel III]: final report. Circulation 2002; 106:3143-421.
147. Goldberg AC. A meta-analysis of randomized controlled studies onthe effects of extended-release niacin in women. Am J Cardiol 2004; 94 121-4.
148. Rosenberg H, Allard D, "Evidence for Caution: Women and StatinUse," Women and Health Protection, Health Canada, June 2007.http://www.whp-apsf.ca/pdf/statinsEvidenceCaution.pdf
149. Kapur N.H, Musunuru K, Clinical efficacy and safety of statins inmanaging cardiovascular risk. Vascul Health Risk Manag 2008; 4:345-53.
150. Kenis I, Tartakover-Matalon S, Cherepnin N, et al. Simvastatin hasdeleterious effects on human first trimester placental explants.Hum. Reproduct 2005; 20 2866-72.
151. Johnson M, Ramey E, Ramwell P.W. Sex and age differences inhuman platelet aggregation. Nature 1975; 253: 355-7.
152. Zuern C.S, Lindemann S, Gawaz M. Platelet function and responseto aspirin: gender-specific features and implications for femalethrombotic risk and management. Semin Thromb Hemost 2009; 35:295-306.
153. Berger J.S, Roncaglioni M.C, Avanzini F, et al. Aspirin for theprimary prevention of cardiovascular events in women and men: asex-specific meta-analysis of randomized controlled trials. J AmMed Ass 2006; 295: 306-13.
154. Boersma E, Harrington RA, Moliterno DJ, et al. Platelet glycoproteinIIb/IIIa inhibitors in acute coronary syndromes: a metaanalysisof all major randomised clinical trials. Lancet 2002; 359:189-98.
155. Escolar G, Bastida E, Garrido M, et al. Sex related differences inthe effects of aspirin on the interaction of platelets with subendothelium. Thromb Res 1986; 44: 837-47.
156. Levin R.I. The puzzle of aspirin and sex. N Engl J Med 2005; 352:1366-8.
157. Iakovou I, Dangas G, Mehran R, et al. Gender differences in clinicaloutcome after coronary artery stenting with use of glycoproteinIIb/IIIa inhibitors. Am J Cardiol 2002; 89: 976-9.
158. Clyne CA. Antithrombotic therapy in the primary and secondaryprevention of coronary-related death and infarction: focus on genderdifferences. Cardiol 1990; 77 (Supp 2): 99-109.
159. Rich-Edwards JW, Rich-Edwards JW, Manson JE, et al. The primaryprevention of coronary heart disease in women. N Engl J Med1995; 332: 1758 66.
160. Kelton JG, Carter CJ, Rosenfeld J, Sex-related differences in theefficacy of acetylsalicylic acid (ASA): the absorption of ASA andits effect on collagen-induced thromboxane B2 generation. ThrombRes 1981; 24: 163-8.
161. Harrison MJ, Weisblatt E. A sex difference in the effect of aspirinon "spontaneous" platelet aggregation in whole blood. ThrombHaemost 1983; 50: 773-4.
162. Gum PA, Kottke-Marchant K, Poggio ED, et al. Profile and prevalenceof aspirin resistance in patients with cardiovascular disease. Am J Cardiol 2001; 88: 230-5.
163. Spranger M, Aspey BS, Harrison MJ. Sex difference in antithromboticeffect of aspirin. Stroke 1989; 20: 34-37.
164. Antiplatelet Trialists' Collaboration. Collaborative meta-analysis ofrandomised trials of antiplatelet therapy for prevention of death, AMI, and stroke in high risk patients. Brit Med J 2002; 324: 71-86.
165. Antiplatelet Trialists' Collaboration. Collaborative overview ofrandomised trials of antiplatelet therapy: prevention of death, myocardialinfarction, and stroke by prolonged antiplatelet therapy invarious categories of patients. Brit Med J 1994; 308: 81-106.
166. Ridker PM, Cook NR, Lee IM, et al. A randomized trial of lowdoseaspirin in the primary prevention of cardiovascular disease inwomen. N Engl J Med 2005; 352: 1293-304.
167. Qayyum R, Becker DM, Yanek LR, Moy TF, Becker LC, Faraday N, Vaidya D. Platelet inhibition by aspirin 81 and 325 mg/day inmen versus women without clinically apparent cardiovascular disease. Am J Cardiol 2008; 101: 1359-63.
168. Cho L, Topol EJ, Balog C, et al. Clinical benefit of glycoproteinIIb/IIIa blockade with Abciximab is independent of gender: pooledanalysis from EPIC, EPILOG and EPISTENT trials. Evaluation of7E3 for the Prevention of Ischemic Complications. Evaluation inPercutaneous Transluminal Coronary Angioplasty to ImproveLong-Term Outcome with Abciximab GP IIb/IIIa blockade.Evaluation of Platelet IIb/IIIa Inhibitor for Stent. J Am Coll Cardiol 2000; 36: 381-6.
169. Alexander, K, Chen AY, Roe MT, et al. For the CRUSADE Investigators.Sex differences in major bleeding with glycoproteinIIb/IIIa inhibitors: results from CRUSADE. Circulation 2006; 114:1380-7.
170. Alexander K, Chen AY, Roe MT, et al. CRUSADE InvestigatorsExcess dosing of antiplatelet and antithrombin agents in the treatmentof non-ST-segment elevation acute coronary syndromes. JAm Med Ass 2005; 294: 3108-16.
171. Lansky A, Pietras C, Costa RA, et al. Gender differences in outcomesafter primary angioplasty versus primary stenting with andwithout abciximab for acute myocardial infarction: results of theControlled Abciximab and Device Investigation to Lower Late AngioplastyComplications [CADILLAC] trial. Circulation 2005; 111:1611-8.
172. Kirtane A, Piazza G, Murphy SA, et al. For the TIMI Study GroupCorrelates of bleeding events among moderate- to high-risk patientsundergoing percutaneous coronary intervention and treatedwith eptifibatide. Observations from the PROTECT-TIMI-30 Trial. J Am Coll Cardiol 2006; 47: 2374-9.
173. Gillum RF, Mussolino ME, Madans JH. Diabetes mellitus, coronaryheart disease incidence, and death from all causes in AfricanAmerican and European American women: the NHANES I epidemiologicfollow-up study. J Clin Epidemiol 2000; 53: 511-8.
174. Gorton HJ, Warren ER, Simpson NAB, et al. Thromboelastographyidentifies sex-related differences in coagulation. Anesth Analg 2000; 91: 1279-81.
175. Wittkowsky A, Whitely K, Devine E, et al. Effect of age on internationalnormalized ratio at the time of major bleeding in patientstreated with warfarin. Pharmacother 2004; 24 600-605.
176. Rieder MJ, Reiner AP, Gage BF, et al. Effect of VKORC1 haplotypeson transcriptional regulation and warfarin dose. N Engl JMed 2005; 352: 2285-93.
177. Veenstra D, Blough DK, Higashi MK, et al. CYP2C9 haplotypestructure in European American warfarin patients and associationwith clinical outcomes. Clin Pharmacol Ther 2005; 77 353-64.
178. Kamali F, Khan TI, King BP, et al. Contribution of age, body size,and CYP2C9 genotype to anticoagulant response to warfarin. ClinPharmacol Ther 2004; 75: 204-12.
179. Poli D, Antonucci E, Grifoni E, et al. Gender differences in strokerisk of atrial fibrillation patients on oral anticoagulant treatment. Thromb Haemost 2009; 101: 938-42.
180. Cosma Rochat M, Waeber G, Wasserfallen JB. Hospitalizedwomen experiencing an episode of excessive oral anticoagulationhad a higher bleeding risk than men. Womens Health (Larchmt) 2009; 18: 321-6.
181. Gomberg-Maitland M, Wenger NK, Feyzi J, et al. Anticoagulationin women with non-valvular atrial fibrillation in the stroke preventionusing an oral thrombin inhibitor (SPORTIF) trials. Eur Heart J 2006; 27: 1947-53.
182. Hughes M, Lip GYH. Guideline Development Group for the NICEnational clinical guideline for management of atrial fibrillation inprimary and secondary care. Risk factors for anticoagulationrelatedbleeding complications in patients with atrial fibrillation: asystematic review. Q J Med 2007; 100: 599-607.
183. Sandberg M, Johansson I, Christensen M, et al. The impact ofCYP2C9 genetics and oral contraceptives on cytochrome P450 2C9phenotype. Drug Metab Dispos 2004; 32: 484-9.
184. Rejnmark L, Vestergaard P, Mosekilde L, et al. Fracture risk inusers of oral anticoagulants: a nationwide case-control study. InterJ Cardiol 2007; 118: 338-44.
185. Duhl AJ, Paidas MJ, Ural SH, et al. Pregnancy and ThrombosisWorking Group. Antithrombotic therapy and pregnancy: consensusreport and recommendations for prevention and treatment of venousthromboembolism and adverse pregnancy outcomes. Am JObstet Gynecol 2007; 197: 457.e1-21.
186. Dauerman HL, Andreou C, Perras MA, et al. Predictors of bleedingcomplications after rescue coronary interventions. J ThrombThrombolysis 2000; 10: 1083-8.
187. Lenderink T, Boersma E, Ruzyllo W, et al. Bleeding events withabciximab in acute coronary syndromes without early revascularization:An analysis of GUSTO IV-ACS. Am Heart J 2004; 147:865-73.
188. Moscucci M, Fox KA, Cannon CP, et al. Predictors of major bleedingin acute coronary syndromes: the Global Registry of AcuteCoronary Events (GRACE). Eur Heart J 2003; 24 1815-23.
189. Jang IK, Baron SJ, et al. Argatroban therapy in women with heparin-induced thrombocytopenia. Womens Health [Larchmt] 2007;16 895-901.
190. Schindewolf M, Schwaner S, Wolter M, et al. Incidence and causesof heparin-induced skin lesions. CMAJ 2009; 18: 477-91.